Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
Gross Margin
Jiang Zhong Pharmaceutical Co Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
|
14.3B CNY |
64%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
775.3B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.9B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
228.6B CHF |
73%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
174.1B GBP |
82%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
196B CHF |
75%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
219.3B USD |
81%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
140B USD |
74%
|
Jiang Zhong Pharmaceutical Co Ltd
Glance View
Jiang Zhong Pharmaceutical Co Ltd. has etched its mark in the bustling landscape of China's pharmaceutical industry by embracing a strategic blend of traditional Chinese medicine (TCM) and modern medical practices. Founded in 1969 and headquartered in Wuhan, this company has steadily navigated the dynamic tides of China's healthcare sector. Jiang Zhong specializes in producing and marketing a wide array of TCM products, which are deeply rooted in ancient Chinese medical philosophies and practices. These offerings cater to various health needs, including gastrointestinal management, respiratory treatments, and nutritional supplements, which resonate well with China's rich cultural heritage of natural health solutions. The company's commitment to quality and efficacy has allowed it to carve out a substantial market niche where tradition meets innovation. Making money for Jiang Zhong Pharmaceutical Co Ltd. revolves around its robust distribution networks and strong brand presence across key domestic markets. The company has invested in extensive research and development initiatives to ensure its product line remains relevant and effective in addressing modern health challenges, alongside its traditional product offerings. By leveraging a diverse marketing strategy that includes partnerships with healthcare institutions, direct consumer promotions, and digital platforms, Jiang Zhong successfully taps into both local and international markets. Additionally, the company enhances its profitability through economies of scale and strategic cost management, allowing it to maintain competitive pricing while achieving substantial revenue growth. This balanced approach of blending tradition with innovation continues to fortify Jiang Zhong Pharmaceutical's position as a respected entity in both TCM and broader pharmaceutical realms.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Jiang Zhong Pharmaceutical Co Ltd's most recent financial statements, the company has Gross Margin of 63.7%.
You don't have any saved screeners yet